tirzepatide and semaglutide as Compared with for the Treatment of Obesity Tirzepatide or semaglutide, weight loss

In a 12-month study of 339 Second Nature members published in JMIR Formative Research, participants on tirzepatide lost an average of 22.1% of their body weight, and those on semaglutide lost 17.1% 11

Similarly, a clinical study involving patients with coronary artery disease demonstrated that 12 weeks of L-carnitine supplementation resulted in reduced malondialdehyde levels, increased circulating L-carnitine concentrations, and enhanced activities of catalase and glutathione peroxidase enzymes compared to the placebo group

Acetyl-L-carnitine and Alzheimer's disease

Dietrich Hauffe, Ph.D

Irene Romera: conception and design of the work

Kelly Dineley) and Animal Resource Center at UTMB for the resources provided for the animal studies